Literature DB >> 30185415

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Andrew L Mammen1, Arun Rajan2, Katherine Pak3, Tanya Lehky4, Livia Casciola-Rosen5, Renee N Donahue6, Lauren M Lepone6, Anastasia Zekeridou7, Sean J Pittock7, Raffit Hassan2, Jeffrey Schlom6, James L Gulley6,8.   

Abstract

Entities:  

Keywords:  B cells; autoantibodies; autoimmune diseases; autoimmunity; polymyositis

Mesh：

Substances：

Year:  2018        PMID： 30185415      PMCID： PMC6447048          DOI： 10.1136/annrheumdis-2018-213777

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  Early B cell changes predict autoimmunity following combination immune checkpoint blockade.

Authors:  Rituparna Das; Noffar Bar; Michelle Ferreira; Aaron M Newman; Lin Zhang; Jithendra Kini Bailur; Antonella Bacchiocchi; Harriet Kluger; Wei Wei; Ruth Halaban; Mario Sznol; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  J Clin Invest       Date:  2018-01-08       Impact factor: 14.808

2.  Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

Authors:  Christopher R Heery; Geraldine O'Sullivan-Coyne; Ravi A Madan; Lisa Cordes; Arun Rajan; Myrna Rauckhorst; Elizabeth Lamping; Israel Oyelakin; Jennifer L Marté; Lauren M Lepone; Renee N Donahue; Italia Grenga; Jean-Marie Cuillerot; Berend Neuteboom; Anja von Heydebreck; Kevin Chin; Jeffrey Schlom; James L Gulley
Journal:  Lancet Oncol       Date:  2017-03-31       Impact factor: 41.316

3.  B-cell lymphopenia and hypogammaglobulinemia in thymoma patients.

Authors:  L Montella; A M Masci; G Merkabaoui; F Perna; L Vitiello; L Racioppi; G Palmieri
Journal:  Ann Hematol       Date:  2003-04-25       Impact factor: 3.673

Review 4.  Thymoma associated with autoimmune diseases: 85 cases and literature review.

Authors:  C Bernard; H Frih; F Pasquet; S Kerever; Y Jamilloux; F Tronc; B Guibert; S Isaac; M Devouassoux; L Chalabreysse; C Broussolle; P Petiot; N Girard; P Sève
Journal:  Autoimmun Rev       Date:  2015-09-25       Impact factor: 9.754

5.  Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.

Authors:  Karen Kelly; Jeffrey R Infante; Matthew H Taylor; Manish R Patel; Deborah J Wong; Nicholas Iannotti; Janice M Mehnert; Anja H Loos; Helga Koch; Isabell Speit; James L Gulley
Journal:  Cancer       Date:  2018-02-22       Impact factor: 6.860

Review 6.  Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.

Authors:  Jia-Hung Chen; Kang-Yun Lee; Chaur-Jong Hu; Chen-Chih Chung
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817
  6 in total
  25 in total

Review 1.  Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.

Authors:  Elizabeth A Lippner; David B Lewis; William H Robinson; Tamiko R Katsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-06-22

Review 2.  Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.

Authors:  Alice Tison; Soizic Garaud; Laurent Chiche; Divi Cornec; Marie Kostine
Journal:  Nat Rev Rheumatol       Date:  2022-10-05       Impact factor: 32.286

Review 3.  Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.

Authors:  Md Mominur Rahman; Tapan Behl; Md Rezaul Islam; Md Noor Alam; Md Mohaimenul Islam; Ali Albarrati; Mohammed Albratty; Abdulkarim M Meraya; Simona Gabriela Bungau
Journal:  Molecules       Date:  2022-06-13       Impact factor: 4.927

Review 4.  Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.

Authors:  M Villagrán-García; R Velasco
Journal:  Neurol Sci       Date:  2022-02-17       Impact factor: 3.830

Review 5.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 6.  Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.

Authors:  Laura C Cappelli; Clifton O Bingham
Journal:  Arthritis Rheumatol       Date:  2021-03-05       Impact factor: 10.995

7.  Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.

Authors:  Luca Diamanti; Alberto Picca; Paola Bini; Matteo Gastaldi; Enrico Alfonsi; Anna Pichiecchio; Eugenia Rota; Roberta Rudà; Francesco Bruno; Veronica Villani; Edvina Galiè; Alberto Vogrig; Mariarosaria Valente; Marco Zoccarato; Valentina Poretto; Bruno Giometto; Carolina Cimminiello; Michele Del Vecchio; Enrico Marchioni
Journal:  Neurol Sci       Date:  2021-08-23       Impact factor: 3.307

8.  Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments.

Authors:  Anastasia Zekeridou; Masoud Majed; Ioannis Heliopoulos; Vanda A Lennon
Journal:  Thorac Cancer       Date:  2019-02-27       Impact factor: 3.500

Review 9.  Narrative review of immunotherapy in thymic malignancies.

Authors:  Jose Carlos Benitez; Benjamin Besse
Journal:  Transl Lung Cancer Res       Date:  2021-06

10.  Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.

Authors:  Elia Sechi; Svetomir N Markovic; Andrew McKeon; Divyanshu Dubey; Teerin Liewluck; Vanda A Lennon; A Sebastian Lopez-Chiriboga; Christopher J Klein; Michelle Mauermann; Sean J Pittock; Eoin P Flanagan; Anastasia Zekeridou
Journal:  Neurology       Date:  2020-08-13       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.